{"name":"Calithera Biosciences, Inc","slug":"calithera-biosciences-inc","ticker":"","exchange":"","domain":"calithera.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-03-12","type":"pipeline","source":"GlobeNewswire","summary":"Pharmaceutical and Biotechnology Royalty Rates Agreements - GlobeNewswire","headline":"Pharmaceutical and Biotechnology Royalty Rates Agreements","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTE9uSDlYWEpJYXdhQ2drQzhYOHJLd0twQ2Y1WE9rdGlISEk2ZngwWG9ETDNGMHpKQ2Utb0tVcGFNTGVvdEt6VjN1aWE0YWlMaThtd3l2TVdYQ3Z0cEw1RDJFZHlkZnU2WEZUMTdJdGd3ZHFzNUk?oc=5","date":"2025-10-15","type":"trial","source":"Taylor & Francis Online","summary":"HERTHENA-PanTumor01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated advanced solid tumors: Future Oncology: Vol 21, No 25 - Taylor & Francis Online","headline":"HERTHENA-PanTumor01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated advanced solid tumors: F","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMia0FVX3lxTE1wY04wUHpRWFVrTnBfOVBoSnVjTkRxMUhQT056dnR2bkhwNWhJaGk0a0ViZ1M1anFXT0pSY0lLNXItc0FWS1RIMkpuc1RxUlFJSkJpS2pyY19SaVhJaHlMallkeGRscU1lOE1N?oc=5","date":"2025-02-13","type":"trial","source":"Wiley Online Library","summary":"A Phase IB Trial of Selinexor in Combination With Immune Checkpoint Blockade in Patients With Advanced Renal Cell Carcinoma - Wiley Online Library","headline":"A Phase IB Trial of Selinexor in Combination With Immune Checkpoint Blockade in Patients With Advanced Renal Cell Carcin","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxPQWhRNkJzeEc4SF9YWXRibnlmU3RlNGd1V2drRFhBb3R3b01QdFBPaGlHU1RvR1RybFhkU21iX2QyMUVlX3JrbWhRUUduZmpjWFhVZHhnV2F5WlcyZlVHM04zT2RDeDZWcVB6MnRKQkEwYXJOOUpja05uMGRIaTNHeEpXSUZpempYbEI3dEkzcG9nRlVjcldJ?oc=5","date":"2023-09-18","type":"trial","source":"Oncology Pipeline","summary":"Bayer looks to clinical validation for $1.5bn Vividion deal | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline","headline":"Bayer looks to clinical validation for $1.5bn Vividion deal | ApexOnco - Clinical Trials news and analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxQVjU3U2V4MUgtY1pwVW1YX1o4VjVjU3plLXBaeXphNXJMQVpZbXRnalVqbzNsNnlCWXB6VEduclYzekJ5M18xNE81VXU0OTZ6Rm1JdkdqbXJVblJSS2xRNE41a1hpRDBIQURPZnVkSExDRGd4ck1lQlY0dXJ2STQycWhBM3k1UnFRWWdzOU9PdzN3WFJxSXhmallVbTdCNWxiOHZlTG9tN0RzTmgxUl9tQ1Zn?oc=5","date":"2023-05-10","type":"pipeline","source":"The Business Journals","summary":"Susan Molineaux is at it again: Weeks after biotech closes, she lands as CEO of Para Therapeutics - The Business Journals","headline":"Susan Molineaux is at it again: Weeks after biotech closes, she lands as CEO of Para Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxPVXN4bDg2V2RkNVdJbFNBWER2TzJPU19PS3hZdTJkZG5ITnpfTHFqZElVVVdHYWQ0aEptQTRZZWZ1Zm5TVHd5SzFrYTFla1gxbnJNbmxHRkZzb05tQnlUZDVmWm5Gb1VjRGRjdW5jUGdmNGdyaEtxTFYydHB3YnZXQW1yOWNoMDBuenVHSXBCR3NuWU1JTGZHeFhieWxGRVFUeXJtN0cxT0RveFRZSzB4aQ?oc=5","date":"2023-01-10","type":"trial","source":"fiercebiotech.com","summary":"Cash-strapped Calithera closes down in shadow of enrollment delays to cancer trials - fiercebiotech.com","headline":"Cash-strapped Calithera closes down in shadow of enrollment delays to cancer trials","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxONGZVcjBBR0EyZ1pUQWtkN3o5VEFPOG1UaC0tVjZfb3NZdk9lZ01ZeXNJTDFlekFTbElJcmJBRWgtREpzOTNpbUtCXzZySFFCelFmWHh4OG5SVkNDME56Q0NrQlk5R25HbXdyOWVrMi1sX0NlaHpiR0lOamVXbEN5STVtdDhycVBiNzBJaWRPNnBrRk81Z1BN?oc=5","date":"2023-01-09","type":"pipeline","source":"Yahoo Finance","summary":"Calithera Biosciences Stock Nosedives On Complete Liquidation, Dissolution - Yahoo Finance","headline":"Calithera Biosciences Stock Nosedives On Complete Liquidation, Dissolution","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiW0FVX3lxTE50NE11N2lRSHhHN1VQb1dnLVlmZjBQTGU0dGxwU0tJSG9hVUxNYXJVZ0I1aHBCdVlVbHNKVVdpQzlrSVN5cmxLX3pRQlJDQnlGQXVkeWE4eEcyTVk?oc=5","date":"2022-12-20","type":"pipeline","source":"EurekAlert!","summary":"3D-patient tumor avatars: Maximizing their potential for next-generation precision oncology - EurekAlert!","headline":"3D-patient tumor avatars: Maximizing their potential for next-generation precision oncology - EurekAlert!","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9aTF9YUDB3ZG1GOHQtSTlZZW9sR0ttTVdfY2ZLTnhiamstWTJydUdEdl9SRENQS29MMmNXV2hqUUZ2V1IyVlFyWE9JaG8yOXIzY0pBd3oxdUpmVTFqSkc0?oc=5","date":"2022-08-23","type":"trial","source":"Nature","summary":"Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial - Nature","headline":"Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxOQ2k1dkVBQWxLZE84dGNzeDNTeHBKbzlOem5pM1pTcUZ3b3E1QzRLcDJDblFlVHlQZE94STlrQ00xMDZwUGRhd3NoN1I1bVJNNm9Td2pfZ1I0UThDLUEyM1ZWUERsdHZVb3Myb3BxV0Rrb2Y4ajdPb0RZWEdVajZ3S2E5R1JGQ3JvZDVlNzNVMVp3aTJnWTVzZXRBd1VycHBWelZFcHd0NDYwMTVQRkNF?oc=5","date":"2021-10-19","type":"deal","source":"BioSpace","summary":"Calithera Biosciences Scores Two Complementary Oncology Compounds in Takeda Deal - BioSpace","headline":"Calithera Biosciences Scores Two Complementary Oncology Compounds in Takeda Deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgJBVV95cUxOZTRvUXA1eGNDbUxhNWdDbVVfaTFDdGNCalFjZ0VNRjNzRi13ZWRDNkkxYVh0dEgyVnQxbnBWa2lnd0xNVGZfdlQ2SDNiUXNKRTF2dGtWZHBKUnFZY0RnLXZUa0lzdllTY01oV3pwelNfQ1djR1VvTElxUGR4TTFUYVlXXzE3WGZnMmpDMWlDckpMRGliaVplUkJIRjBFcFg4UklpY2staDFLMTZDUXdiMHRoek1WTTlndkJpWkEzM2VjMXJVVHJiUXF5blhRMVVXUVJUSDNKX1FlOWR0U1p1dk5WNjB4TExXcnljNlNDUkZpa3dwam9BNHU5VVRSeFM1aGVtdnNCNzlUSE1MUXdEQXJsTWdDVk5RNWZ3d3JOSWc0M0pPY3c?oc=5","date":"2021-05-17","type":"deal","source":"prnewswire.com","summary":"Antengene and Calithera Biosciences Enter into Worldwide Exclusive License Agreement to Develop and Commercialize CD73 Inhibitor CB-708 (ATG-037) - prnewswire.com","headline":"Antengene and Calithera Biosciences Enter into Worldwide Exclusive License Agreement to Develop and Commercialize CD73 I","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxNWlVGUk45b0t1cWdnVlZhZTVHaE5ySHlKX0tnSEtmM0U4ZEFkdU1Rdjc0dUdXUnFBdHk0VVN3X1ppZmd0bHdvUy1SaHlQbmpHMms2NDB0ZWk1MnlYQmh1dDE2bDdRc2NWU2pMLUJZUm9RbUZFLVd0WUlyMlA5R09rMVZ4V3d3NGtWR2lPa0hpN21UM1NOOWRMdUEwUUdqd18yUjh3OFJrU3k?oc=5","date":"2020-01-08","type":"pipeline","source":"statnews.com","summary":"A new biotechnology and pharmaceutical industry commitment to patients and the public - statnews.com","headline":"A new biotechnology and pharmaceutical industry commitment to patients and the public","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}